Pyxis Oncology, Inc. (PYXS) Financial Statements (2026 and earlier)

Company Profile

Business Address 321 HARRISON AVENUE
BOSTON, MA 02118
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:66,900126,900119,300179,293274,735
Cash and cash equivalent15,42219,4739,664179,293274,735
Short-term investments51,435107,458109,634  
Other undisclosed cash, cash equivalents, and short-term investments43(31)2  
Restricted cash and investments1,4721,4721,4721,4721,472
Receivables   21598 
Prepaid expense3,7764,0373,8345,8472,466
Other undisclosed current assets(43)31(23)(598) 
Total current assets:72,105132,440124,604186,612278,673
Noncurrent Assets
Operating lease, right-of-use asset11,41812,24212,94213,602232
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization7,9979,89911,87211,1651,007
Intangible asset, including goodwill, after accumulated amortization (514)2,60024,308  
Intangible asset, excluding goodwill, after accumulated amortization (514)2,60024,308  
Other noncurrent assets     109
Other undisclosed noncurrent assets 514    
Total noncurrent assets:19,41524,74149,12224,7671,348
TOTAL ASSETS:91,520157,181173,726211,379280,021
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19,43916,23016,86731,63418,543
Accounts payable10,8854,8593,8967,09711,951
Accrued liabilities8,55411,37112,97124,5376,592
Deferred revenue   7,660  
Other undisclosed current liabilities1,6921,4501,232 165
Total current liabilities:21,13117,68025,75931,63418,708
Noncurrent Liabilities
Long-term debt and lease obligation23100   
Finance lease, liability23100   
Liabilities, other than long-term debt16,95818,65022,26318,921 
Deferred income tax liabilities   2,164  
Operating lease, liability16,95818,65020,09918,921 
Total noncurrent liabilities:16,98118,75022,26318,921 
Total liabilities:38,11236,43048,02250,55518,708
Equity
Equity, attributable to parent53,408120,751125,704160,824261,313
Common stock6360453432
Additional paid in capital496,469484,077411,821373,225352,999
Accumulated other comprehensive income 5317063  
Accumulated deficit(443,177)(363,556)(286,225)(212,435)(91,718)
Total equity:53,408120,751125,704160,824261,313
TOTAL LIABILITIES AND EQUITY:91,520157,181173,726211,379280,021

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues13,85816,1461,776  
Sublease income2,5752,9261,776  
Cost of revenue (2,388)(475)   
Other undisclosed gross profit     
Gross profit:11,47015,6711,776  
Operating expenses(95,890)(105,131)(82,196)(123,481)(69,717)
Other undisclosed operating loss  (1,776)  
Operating loss:(84,420)(89,460)(82,196)(123,481)(69,717)
Nonoperating income (expense)6,1859,9658,4062,764(6,027)
Investment income, nonoperating3,6107,0396,6302,76423
Loss from continuing operations before equity method investments, income taxes:(78,235)(79,495)(73,790)(120,717)(75,744)
Loss from equity method investments     (231)
Loss from continuing operations before income taxes:(78,235)(79,495)(73,790)(120,717)(75,975)
Income tax expense (benefit)(1,386)2,164   
Loss from continuing operations:(79,621)(77,331)(73,790)(120,717)(75,975)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(75,975)
Net loss available to common stockholders, diluted:(79,621)(77,331)(73,790)(120,717)(75,975)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net loss:(79,621)(77,331)(73,790)(120,717)(75,975)
Other comprehensive income (loss)(117)10763  
Comprehensive loss, net of tax, attributable to parent:(79,738)(77,224)(73,727)(120,717)(75,975)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: